Cue Biopharma grants 200,000 stock options to SVP

Cue Biopharma, Inc. reported that SVP and General Counsel Colin Sandercock received a grant of stock options on Common Stock.

Rhea-AI Filing Summary

Cue Biopharma, Inc. reported that SVP and General Counsel Colin Sandercock received a grant of stock options on Common Stock. The award covers 200,000 stock options with an exercise price of $0.29 per share and an expiration date of April 8, 2036.

These options vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Sandercock holds 200,000 stock options directly, reflecting a routine compensation-related equity award rather than an open-market transaction.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Sandercock Colin

Role SVP, GENERAL COUNSEL

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	200,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 200,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

Key Figures

Stock options granted: 200,000 options Exercise price: $0.29 per share Expiration date: April 8, 2036 +2 more

5 metrics

Stock options granted 200,000 options Grant to SVP and General Counsel on April 9, 2026

Exercise price $0.29 per share Exercise price for granted stock options

Expiration date April 8, 2036 Expiration for 200,000 stock options

Underlying shares 200,000 shares Common Stock underlying the granted options

Total options held after grant 200,000 options Directly held by Colin Sandercock following this transaction

Key Terms

Stock Option (right to buy), exercise price, vests over four years, semi-annual installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.2900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests over four years financial

"This stock option becomes exercisable over four years"

A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.

semi-annual installments financial

"the remainder vesting in equal, semi-annual installments thereafter"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

What did Cue Biopharma (CUE) disclose in this Form 4 filing?

Cue Biopharma disclosed that SVP and General Counsel Colin Sandercock received a grant of stock options. The award covers 200,000 options on Common Stock as part of equity compensation, rather than an open-market stock purchase or sale.

How many Cue Biopharma (CUE) stock options were granted to Colin Sandercock?

Colin Sandercock was granted 200,000 stock options on Cue Biopharma Common Stock. These options represent a compensation award and give him the right to buy shares at a fixed price if and when they vest and are exercised.

What is the exercise price of the new Cue Biopharma (CUE) stock options?

The newly granted stock options have an exercise price of $0.29 per share. This means Sandercock can purchase Cue Biopharma Common Stock at $0.29 per share once the options vest and he chooses to exercise them before expiration.

When do the Cue Biopharma (CUE) stock options granted to Sandercock vest?

The options vest over four years. 25% of the award vests on the one-year anniversary of the grant date, and the remaining 75% vests in equal semi-annual installments, aligning vesting with longer-term employment and performance.

What is the expiration date of Colin Sandercock’s Cue Biopharma (CUE) stock options?

The granted stock options expire on April 8, 2036. If the options are not exercised by that date, they will lapse, and Sandercock will no longer have the right to purchase shares at the $0.29 exercise price.

Is this Cue Biopharma (CUE) Form 4 filing an open-market stock purchase or sale?

No. The filing reflects a grant of stock options as compensation, coded as an acquisition (A). It does not involve Sandercock buying or selling Cue Biopharma shares in the open market, but receiving rights to buy stock in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/10/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Colin

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERAL COUNSEL

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.29	04/09/2026		A		200,000		(1)	04/08/2036	Common Stock	200,000	$0.0	200,000	D

Explanation of Responses:

1. This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

	/s/ Colin Sandercock	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)